<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03624101</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-300001363</org_study_id>
    <nct_id>NCT03624101</nct_id>
  </id_info>
  <brief_title>Novel Therapeutic Approaches for Treatment of CF Patients With W1282X Premature Termination Codon Mutations</brief_title>
  <official_title>Novel Therapeutic Approaches for Treatment of CF Patients With W1282X Premature Termination Codon Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on previous clinical findings, the investigator hypothesize that ivacaftor will have&#xD;
      synergistic effects with drugs that facilitate truncated but partially active W1282X CFTR&#xD;
      protein processing (tezacaftor) in patients with W1282X CFTR. In the current study, the&#xD;
      investigators propose to directly test the efficacy of tezacaftor/ivacaftor (TEZ/IVA) and&#xD;
      Trikafta for W1282X CFTR therapy in the clinic in comparison to ivacaftor alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 11% of CF patients have premature termination codons (PTC), causing truncated&#xD;
      CFTR with little to no function. No approved therapies exist for patients with PTC mutations&#xD;
      including W1282X, a unique mutation exhibiting partial CFTR activity even in its truncated&#xD;
      form. CFTR modulators alone enhanced CFTR function in patient cells from W1282X/G542X CFTR.&#xD;
      Several published studies have shown CFTR modulators alone and/or in combination with&#xD;
      readthrough (RT) agents benefit W1282X CFTR. Clinical studies further support an aspect of&#xD;
      this notion, where two W1282X patients showed beneficial effect to Ivacaftor treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2018</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>lung function</measure>
    <time_frame>24 weeks</time_frame>
    <description>change in Fev1</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Trikafta</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If the participant is not on a current modulator, they will take Trikafta for 28 days followed by a 28 day off period. This cycle will be continued for 168 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Symdeko/Trikafta</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If the participant currently takes Symdeko , they will take Trikafta for a 28 day period followed by Symdeko for a 28 day period. This cycle will be continued for 168 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ivacaftor/Trikafta</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If the participant currently takes Ivacaftor , they will take Trikafta for a 28 day period followed by Ivacaftor for a 28 day period. This cycle will be continued for 168 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trikafta</intervention_name>
    <description>CFTR modulator</description>
    <arm_group_label>Trikafta</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>symdeko/Trikafta</intervention_name>
    <description>CFTR modulator</description>
    <arm_group_label>Symdeko/Trikafta</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivacaftor/Trikafta</intervention_name>
    <description>CFTR modulator</description>
    <arm_group_label>Ivacaftor/Trikafta</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Evidence of signed and dated informed consent/assent document(s) indicating that the&#xD;
             subject (and/or his parent/legal guardian) has been informed of all pertinent aspects&#xD;
             of the trial&#xD;
&#xD;
               -  Age ≥ 18 yrs&#xD;
&#xD;
               -  Body weight ≥ 16 kg&#xD;
&#xD;
               -  Diagnosis of CF and documentation of the presence of a nonsense mutation of the&#xD;
                  CFTR gene, as determined by historical genotyping&#xD;
&#xD;
               -  Ability to perform a valid, reproducible spirometry with demonstration of FEV1 ≥&#xD;
                  30% and ≤ 90% of predicted for age, gender, and height&#xD;
&#xD;
               -  In subjects who are sexually active, willingness to abstain from sexual&#xD;
                  intercourse or employ a barrier or medical method of contraception during the&#xD;
                  study drug administration&#xD;
&#xD;
               -  Willingness and ability to comply with all study procedures and assessments&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any change (initiation, change in type of drug, dose modification, schedule&#xD;
             modification, interruption, discontinuation, or re-initiation) in a chronic&#xD;
             treatment/prophylaxis regimen for CF or for CF-related conditions within 2 weeks prior&#xD;
             to screening&#xD;
&#xD;
          -  Ongoing participation in any other therapeutic clinical trial&#xD;
&#xD;
          -  Evidence of pulmonary exacerbation or acute upper or lower respiratory tract infection&#xD;
             (including viral illnesses) within 2 weeks prior to screening&#xD;
&#xD;
          -  History of solid organ or hematological transplantation; positive hepatitis B surface&#xD;
             antigen test; hepatitis C antibody test; or human immunodecifiency&#xD;
&#xD;
          -  Major complication of lung disease (including massive hemoptysis, pneumothorax, or&#xD;
             pleural effusion) within 4 weeks prior to screening&#xD;
&#xD;
          -  Pregnancy or breast-feeding&#xD;
&#xD;
          -  Current smoker or a smoking history of ≥ 10 pack-years (number of cigarette packs/day&#xD;
             x number of years smoked)&#xD;
&#xD;
          -  Prior or ongoing medical condition (eg, renal failure, alcoholism, drug abuse,&#xD;
             psychiatric condition), medical history, physical findings, ECG findings, or&#xD;
             laboratory abnormality that, in the investigator's opinion, could adversely affect the&#xD;
             safety of the subject, makes it unlikely that the course of treatment or follow-up&#xD;
             would be completed, or could impair the assessment of study results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Heather Hathorne, PhD</last_name>
    <phone>205-638-9568</phone>
    <email>hhathorne@peds.uab.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ginger Reeves, BS</last_name>
    <phone>205-638-5970</phone>
    <email>greeves@peds.uab.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather R Hathorne, MAE, RRT</last_name>
      <phone>205-939-9568</phone>
      <email>hhathorne@peds.uab.edu</email>
    </contact>
    <investigator>
      <last_name>Steven M Rowe, MD, MpH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 7, 2018</study_first_submitted>
  <study_first_submitted_qc>August 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2018</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Steven M Rowe</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivacaftor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

